# Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC

> **NCT03573947** · PHASE2 · COMPLETED · sponsor: **Jeffrey Clarke** · enrollment: 46 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03573947
- **Lead sponsor:** Jeffrey Clarke
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-02
- **Primary completion:** 2023-03-12
- **Final completion:** 2023-06-15
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573947, "Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03573947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*